Novo Nordisk offers Wegovy at lowered cost, Hims & Hers Health shares fall

March 06, 2025 01:07 AM AEDT | By Investing

Google News:

Novo Nordisk offers Wegovy at lowered cost, Hims & Hers Health shares fall

Recent News

Independent Study Reveals 236% ROI with Dovetail’s AI-First Customer I...

PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C F...

Sunrun hit by RBC downgrade, target halved on policy, cost risks

Trane Technologies’ Cal Krause Named to Trellis 30 Under 30 List

Investing.com -- Novo Nordisk (NYSE:NVO) is introducing NovoCare Pharmacy, a direct-to-patient delivery option offering Wegovy at a reduced price of $499 per month for certain cash-paying patients.

The program is available to uninsured individuals and those with commercial insurance that does not cover obesity medicines, expanding access to the company’s blockbuster weight-loss drug.

The announcement weighed on shares of Hims Hers Health Inc (NYSE:HIMS), a telehealth provider that offers compounded versions of weight-loss drugs, which fell around 3% in premarket trading Wednesday.

Novo Nordisk U.S.-listed shares climbed nearly 5%.

The move follows the FDA’s recent announcement that the supply shortage of Wegovy has been resolved, with all dose strengths now meeting or exceeding demand.

By offering direct home delivery through CenterWell Pharmacy, Novo Nordisk aims to streamline patient access while reducing reliance on retail pharmacies. The company is also providing support services such as benefit verification, refill reminders, and live case management.

"Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not," said Dave Moore, Executive Vice President of U.S. Operations and President of Novo Nordisk Inc.

He highlighted that over 55 million people in the U.S. now have coverage for weight-loss medications, and the majority of those with insurance pay between $0 and $25 per month for Wegovy.

Novo Nordisk is positioning the program as both a convenience and a safety measure, urging patients to use FDA-approved treatments instead of compounded semaglutide products, which have drawn regulatory scrutiny.

The company plans to extend lower pricing to cash-paying patients using traditional pharmacies in the near future.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.